Colgate-Palmolive Analysts Slash Their Forecasts After Q4 Results

Colgate-Palmolive Company CL posted mixed results for the fourth quarter on Friday.

The company reported a fourth-quarter sales decline of 0.12% year-on-year to $4.94 billion, missing the analyst consensus estimate of $4.98 billion. Organic sales increased by 4.3%. Total Oral, Personal, and Home Care net sales decreased by 0.8% to $3.80 billion. Adjusted EPS of 91 cents beat the consensus estimate of 89 cents.

"This was our sixth consecutive year with organic sales growth at or above our 3% to 5% targeted range. The combination of strong sales growth and operating leverage drove strong bottom-line performance as well, with net income and earnings per share both increasing double digits versus 2023," said Chairman, President, and CEO Noel Wallace.

Colgate said it expects FY25 net sales to be roughly flat, including a mid-single-digit negative impact from foreign exchange.

The company expects organic sales growth to be within its long-term targeted range of 3% to 5%, including the impact of the planned exit from private label pet nutrition in 2025.

Colgate-Palmolive shares fell 0.2% to trade at $86.57 on Monday.

These analysts made changes to their price targets on Colgate-Palmolive following earnings announcement.

Morgan Stanley analyst Dara Mohsenian maintained Colgate-Palmolive with an Overweight and lowered the price target from $111 to $104.
Raymond James analyst Olivia Tong reiterated Colgate-Palmolive with an Outperform and lowered the price target from $110 to $105.
RBC Capital analyst Nik Modi maintained the stock with a Sector Perform and lowered the price target from $101 to $98.
Stifel analyst Mark Astrachan maintained Colgate-Palmolive with a Hold and lowered the price target from $95 to $93.
UBS analyst Peter Grom maintained the stock with a Buy and cut the price target from $104 to $100.

Considering buying CL stock? Here’s what analysts think: